Hospital Pharmacy Unit of the "Centro di Riferimento Oncologico (CRO) di Aviano IRCCS", Via F. Gallini, 33081 Aviano, Italy.
Department of Hospital Pharmacy, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy.
Int J Mol Sci. 2022 Mar 10;23(6):3012. doi: 10.3390/ijms23063012.
The impressive advances in the knowledge of biomarkers and molecular targets has enabled significant progress in drug therapy for crucial diseases such as cancer. Specific areas of pharmacology have contributed to these therapeutic outcomes-mainly targeted therapy, immunomodulatory therapy, and gene therapy. This review focuses on the pharmacological profiles of these therapeutic classes and intends, on the one hand, to provide a systematic definition and, on the other, to highlight some aspects related to pharmacovigilance, namely the monitoring of safety and the identification of potential toxicities and adverse drug reactions. Although clinicians often consider pharmacovigilance a non-priority area, it highlights the risk/benefit ratio, an essential factor, especially for these advanced therapies, which represent the most innovative and promising horizon in oncology.
在生物标志物和分子靶点知识方面取得的令人印象深刻的进展，使得对癌症等关键疾病的药物治疗取得了重大进展。药理学的特定领域为这些治疗结果做出了贡献——主要是靶向治疗、免疫调节治疗和基因治疗。这篇综述重点介绍了这些治疗类别的药理学特征，一方面旨在提供系统的定义，另一方面强调与药物警戒相关的一些方面，即安全性监测以及识别潜在毒性和药物不良反应。尽管临床医生通常认为药物警戒不是优先考虑的领域，但它突出了风险/收益比，这是一个至关重要的因素，特别是对于这些先进的治疗方法，它们代表了肿瘤学中最具创新性和前景的领域。
